4/22/2013

Resolute Integrity's zotarolimus-eluting stent helped reduce target vessel failure rate and proved safe and effective in patients with diabetes, an analysis revealed. Another review showed insulin-treated diabetes patients had higher target lesion failure rates than non–insulin-treated diabetes patients. The results appear in JACC: Cardiovascular Interventions.

Related Summaries